Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Here, we describe micropipette-guided drug administration (MDA) as an alternative method to oral gavage that incentivizes the research animal to ingest treatments readily with minimal stress and discomfort.

Abstract

Oral gavage (OG) with the use of a cannula attached to a syringe is one of the most common methods used to deliver precise dosing of compounds to the stomach of research animals. Unfortunately, this method comes with difficulties for both the operator and the research animal. Studies have shown that OG may lead to complications, including esophagitis, perforation of the esophagus, and inadvertent tracheal drug administration. In addition, OG is associated with increased plasma and fecal corticosterone levels (due to stress), altered blood pressure, and increased heart rate, which could negatively influence or bias study results. A previously developed alternative method termed micropipette-guided drug administration (MDA) incentivizes the animal to consume treatments readily in a minimally invasive manner. Herein, we present examples of the use of the MDA technique with treatments reconstituted in different vehicles and demonstrate effective delivery of the varied treatments to multiple different mouse strains. We further demonstrate that MDA is a technique that decreases the timing and invasiveness of drug administration and does not affect the gut microbiome composition as assessed by quantitative analysis of core gut microbial species. Overall, MDA may offer a less stressful and effective alternative to OG.

Introduction

Drug administration to rodent models is commonly achieved via oral gavage (OG), which consists of administering a liquid preparation directly to the stomach using a cannula attached to a syringe containing the solution. This technique results in a consistent and precise dosage of the treatment to the animal, but also carries multiple disadvantages. OG has been scrutinized for not adequately modeling human dietary exposures1,2. Furthermore, OG increases the risk of unintentional injuries to the upper digestive system (perforation of the esophagus and stomach), aspiration of the administered treatment, and respi....

Protocol

All animal studies were performed following institutional guidelines and under Johns Hopkins University Institutional Animal Care and Use Committee (IACUC) approved protocols M021M197 and M023M195. Mouse strains used (male mice, 7 weeks old) are described in the Table of Materials. The use of male mice was due to their use in the ongoing studies of prostate cancer. The MDA method has previously been shown to be effective in female mice as well7,17

Representative Results

MDA can be used in the oral delivery of bacterial strains in mouse models. C57BL/6J mice were treated with antibiotics (cefoxitin in the drinking water) for 2 days to clear commensal microbial communities before starting the MDA training session. The sweetened condensed milk/water solution was administered once daily consecutively for 3 days prior to treatment administration. Mice were briefly restrained by gentle scruff during MDA treatment administration. On day 4, mice were treated once with PBS (nega.......

Discussion

OG can be a significant source of stress in research animals that may create a confounding variable as previously assessed in multiple studies7,9,11,12,13,14,15,23. Due to the invasiveness of OG, alternate techniques have been employed to minimize the chall.......

Acknowledgements

We would like to acknowledge research support from the Department of Defense Prostate Cancer Research Program Award W81XWH-20-1-0274 and Prostate Cancer Foundation Challenge Award 16CHAL13. We would like to thank and acknowledge Dr. Michelle Rudek, Dr. Noushin Rastkari, Dr. Nicole Anders, and Linping Xu of the Analytical Pharmacology Shared Resource at Johns Hopkins for assistance with equol LC/MS/MS.

....

Materials

NameCompanyCatalog NumberComments
200 µL pipette tipsMettler Toledo17005860
AB SCIEX Triple QTRAP 5500 mass-spectrometric detectorSciexN/A
Akkermansia muciniphila strain muc genomic DNAAmerican Type Culture CollectionBAA-835D-5
Ammonium acetateSigma–Aldrich5.43834
C57BL/6J miceJackson LaboratoriesStrain# 000664
C. scindens strain 35704American Type Culture Collection35704
CefoxitinSagent NDC25021-109-10
Corn oilMedChemExpressHY-Y1888
DMSOSigma-AldrichD2650
ethanolFisher ScientificAC611050040
Formic acidSigma–Aldrich5.33002
FVB/NJ miceJackson LaboratoriesStrain# 001800
GlycerolSigma–AldrichG5516
HexaneFisher Scientific02-002-996
LC-MS grade waterFisher Scientific14-650-357
MethanolFisher Scientific02-003-340
Microtainer serum separator tubeBecton Dickinson02-675-185
Molecular biology grade waterCorning46-000-CI
NSG miceJackson LaboratoriesStrain# 005557
PBSCorning21-031-CV
Qubit DNA HS kitInvitrogenQ32851
Racemic equol-d4Santa Cruz Biotechnologysc-219827
Reinforced Clostridial agarAnaerobe SystemsAS-6061
Reinforced Clostridial brothAnaerobe SystemsAS-606
S-equolMedChemExpressHY-100583
S-equol reference standard for LC-MSCayman Chemical10010173
Single channel pipetteRainin17008652
Streptococcus salivarius genomic DNAAmerican Type Culture CollectionBAA-1024D-5
Sweetened condensed milkCalifornia FarmsB09TGQ7WV8
VSL#3VSL#3B07WX1LVHL
β-glucuronidase from Helix pomatiaSigma–AldrichG7017

References

  1. Vandenberg, L. N., Welshons, W. V., Vom Saal, F. S., Toutain, P. -. L., Myers, J. P. Should oral gavage be abandoned in toxicity testing of endocrine disruptors. Environ Health. 13 (1), 46 (2014).
  2. Craig, M. A., Elliott, J. F.

Explore More Articles

Micropipette guided Drug AdministrationOral GavageRodent ModelsDrug DeliveryAnimal ResearchEsophagitisCorticosterone LevelsHeart RateMinimally Invasive TechniqueGut MicrobiomeTreatment VehiclesMouse StrainsStress Reduction

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved